Ptc Therapeutics (PTCT) Operating Income (2012 - 2026)

Ptc Therapeutics' Operating Income history runs 15 years deep, the most recent figure standing at $149.0 million for Q2 2026.

• In Q2 2026, Operating Income rose 526.17% year-over-year to $149.0 million; the TTM figure through Jun 2026 stood at $125.6 million (down 82.52% YoY), while the FY2025 annual figure was $866.9 million, up 386.52% from the prior year.
• Operating Income for Q2 2026 stood at $149.0 million, up from $45.0 million in the prior quarter.
• The five-year high for Operating Income was $970.2 million in Q1 2025, with the low at -$209.5 million in Q2 2023.
• The 5-year median for Operating Income is -$61.3 million (2022), against an average of -$7.1 million.
• The sharpest annual moves came in 2024 and 2025: Operating Income tumbled 2890.19% in 2024, then soared 2234.57% in 2025.
• Ptc Therapeutics' Operating Income stood at -$200.3 million in 2022, then soared by 102.91% to $5.8 million in 2023, then sank by 2890.19% to -$162.4 million in 2024, then jumped by 56.06% to -$71.3 million in 2025, then jumped by 308.8% to $149.0 million in 2026.
• Business Quant data shows PTCT's Operating Income at $149.0 million in Q2 2026, $45.0 million in Q1 2026, and -$71.3 million in Q4 2025.